Oruka Therapeutics general counsel sells 9,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. General Counsel Paul T. Quinlan exercised employee warrants for 9,000 common shares at $7.8000 per share on November 20, 2026, then sold 9,000 common shares that day: 3,300 at a weighted-average $94.0485, 3,000 at $94.7732, 2,500 at $95.9944 and 200 at $96.6000 per share. The sales were effected under a Rule 10b5-1 trading plan entered into May 15, 2026.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Warrant (right to buy) F6 | 9,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 9,000 | $7.80 | $70K |
| Sale | Common Stock F1, F2 | 3,300 | $94.0485 | $310K |
| Sale | Common Stock F1, F3 | 3,000 | $94.7732 | $284K |
| Sale | Common Stock F1, F4 | 2,500 | $95.9944 | $240K |
| Sale | Common Stock F1, F5 | 200 | $96.60 | $19K |
Footnotes (6)
- F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.40 to $94.38, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.46 to $95.22, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.52 to $96.30, inclusive.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.56 to $96.64, inclusive.
- F6. The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
Employee Warrant (right to buy) technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What happened to Paul T. Quinlan's ORKA employee warrants?
AI-generated analysis. How Rhea-AI works. Not financial advice.